No Data
No Data
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): It is expected that the tight situation of cold medicine production capacity in the second half of 2024 will be alleviated to some extent.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated during an investor relations event on July 30 that the past year has seen sustained sales for the cold category, creating certain pressure on production capacity. The Huazhong South China Production and Manufacturing Center of China Resources Sanjiu in Chengzhou began production at the end of 2023, with production capacity gradually released during the ramp-up process. It is expected that the tense situation of cold medicine production capacity will be eased in the second half of 2024.
China Resources Sanjiu, National Development Bank Ink Financial Services Deal
China resources sanjiu medical & pharmaceutical (000999.SZ) signed a strategic cooperation agreement with the Shenzhen Branch of China Development Bank.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) announced that in order to broaden the company's financing channels and improve the efficiency of financing, the company...
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ):The prescription drug business is still under pressure due to external environment factors.
On July 24th, Gelonghui, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated during an investor relations activity that its prescription drug business has been impacted by external factors. Although hospitals are gradually recovering, there is still some pressure. The company has long insisted on compliant operations and continuously improving its compliance management level. The rectification of the pharmaceutical industry is beneficial to the company's future development.
CICC: Maintains an outperform rating on Chinares Pharma with a target price of HKD 7.3.
CICC released a research report stating that Chinares Pharma (03320) was maintaining its rating of "outperform the industry," with EPS forecasts of $0.69/$0.77 for 2024/2025 remaining unchanged, corresponding to a year-on-year increase of 12.0%/12.2%, with a target price of HK$7.3. On July 17th, the company announced that its subsidiary, China Resources Boya Bio-Pharmaceutical Group, intends to acquire 100% equity of Lvxing Hong Kong Holdings for 1.82 billion yuan. On July 11th, Dong-E-E-Jiao, a subsidiary of the company, released its performance forecast for the first half of 2024, with preliminary estimates of net income attributable to shareholders at 0.695-0.76 billion yuan, a year-on-year increase of 31-43%. CICC's main points of view are as follows:
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): The company expects double-digit growth in revenue in 2024.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated at an investor relations event on July 10th that 2024 will be a key year for the company's new development stage. On the basis of stabilizing existing business, the company will focus on innovative transformation, actively carry out mergers and business cooperation, enhance core capabilities for sustainable growth, and continue to promote the integration and development of KPC Pharmaceuticals, Inc. The company expects revenue to achieve double-digit growth and net income to match revenue growth, and is currently working towards its established goals in an orderly manner.
No Data